An early phase II study of intratumoral P-32 chromic phosphate injection therapy for patients with refractory solid tumors and solitary metastases

Cancer

Volumn 85, Issue 4, 1999, Pages 980-987

  Firusian, Nosrat ^a   Dempke, Wolfram C M ^a,b  

^a Elisabeth Hospital   (Germany)

^b MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

Intratumoral injection; P 32 chromic phosphate; Refractory solid cancers; Response rates; Side effects

Indexed keywords

PHOSPHORUS 32;

ADULT; AGED; ARTICLE; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DRUG EFFICACY; ECHOGRAPHY; FEMALE; HUMAN; INTRATUMORAL DRUG ADMINISTRATION; MALE; METASTASIS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RADIATION DOSE; SCINTIGRAPHY; SOLID TUMOR; THROMBOCYTOPENIA; TREATMENT OUTCOME; TUMOR VOLUME;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA; CARCINOMA, HEPATOCELLULAR; CHROMIUM COMPOUNDS; DIGESTIVE SYSTEM NEOPLASMS; DRUG RESISTANCE, NEOPLASM; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; INJECTIONS, INTRALESIONAL; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASMS; PHOSPHATES; PHOSPHORUS RADIOISOTOPES; SURVIVAL RATE;

EID: 0033557910     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19990215)85:4<980::AID-CNCR28>3.0.CO;2-H     Document Type: Article

References (22)

1. Firusian N. Nuklearmedizinische Therapie des fortgeschrittenen therapierefraktären Thoraxwandrezidivs des Mammakarzinoms. Nucl-Med 1996;35:24-8.
2. Firusian N, Fricke D. Results of P-32 therapy in advanced thoracic wall recurrences [Abstract 10]. Nucl Med Commun 1996;17:2582.
3. Firusian N, Fricke D, Böcher E. Radionuklidtherapie des Thoraxwandrezidivs des Mammakarzinoms. Tumordiagn Ther 1996;17:47-57.
4. Hammersley PAG, Vini L, McCready VR. Unsealed source radiation therapy for solid tumors [Abstract 9]. Nucl Med Commun 1996;17:258.
5. Leksell L, Liden LAA. Therapeutic trial with radioactive isotopes in cystic brain tumors. Radioisotope Technology, Proceedings of Isotope Technical Conference, Medical and Physiological Applications. London: Her Majesty's Stationery Office, 1953:76.
6. Wycis HT, Robbins R, Spoegel-Adolph M. Treatment of a cystic craniopharyngeoma by injection of radioactive P-32.Conf Neurol 1954;14:93-195.
7. Harbert JC. Nuclear medicine therapy. Stuttgart: Thieme; 1987;285-96.
8. Order SE, Siegel JA, Lustig RA. Infusional brachytherapy in the treatment of nonresectable pancreatic cancer: a new radiation modality (preliminary report of the phase I study). Antibody Immunoconjug Radiopharm 1994;7:11-27.
9. Begg AC, Stewart FA, Dewit L. Interactions between cisplatin and radiation in experimental rodent tumors and normal tissues. In: Hill BT, Bellamy AS, editors. Antitumor drug-radiation interactions. Florida: Boca Raton; 1190;153-70.
10. Carde P, Laval F. Effect of cis-dichlorodiammine platinum II and X rays on mammalian cell survival. Int J Radiat Oncol Biol Phys 1981;7:923-7.
11. Rosso W. Antitumoral activity of human fibroblast interferon administered intranodularily. Oncology 1985;42:86-8.
12. Habif DV. Regression of skin recurrences of breast carcinomas treated with intralesional injections of natural interferons alpha and gamma. Cancer Invest 1995;13:165-72.
13. Wildfang I. Intraläsionale Therapie mit β-Interferon bei Metastasen solider Tumoren. Inter Prax 1995;35:81-6.
14. Watanabe N. Recombinant tumor necrosis factor causes regression on patients with advanced malignancies. Oncology 1994;51:360-5.
15. Ijzermans JN. Local treatment of liver metastases with recombinant tumour necrosis factor (rTNF): a phase I study. Neth J Surg 1991;43:121-5.
16. Vlock DR. Phase Ib trial of the effect of peritumoral and intranodal injections of interleukin-2 in patients with advanced squamous cell carcinoma of head and neck: an Eastern Cooperative Oncology Group trial. J Immunother Emphasis Tumor Immunol 1994;15:134-9.
17. Livraghi T, Lazzaroni S, Meloni F, Torzilli G, Vettori C. Intralesional ethanol in the treatment of unresectable liver cancer. World J Surg 1995;16:801-6.
18. Peschel RE, Fogel T, Kacinski B. Iodine-125 implants for carcinoma of the prostate. Int J Radiat Oncol Biol Phys 1985;11:1777-82.
19. Dempke WCM, Shellard SA, Hosking LK, Hill BT. Mechanisms associated with the expression of cispaltin resistance in a human ovarian tumor cell line following exposure to fractionated X-irradiation in vitro. Carcinogenesis 1992;13: 1209-15.
20. Dempke WCM, Hosking LK, Hill BT. Expression of collateral sensitivity to cisplatin, methotrexate, and fluorouracil in a human ovarian carcinoma cell line following exposure to fractionated X-irradiation in vitro. Semin Oncol 1992; 19(Suppl 3):66-72.
21. Dewit L. Combined treatment of radiation and cis-diamminedichloroplatinum(II): a review of experimental and clinical data. Int J Radiat Oncol Biol Phys 1987;13:403-17.
22. Mattern MR, Hofmann GA, McGabe FL. Synergistic cell killing by ionizing radiation and topoisomerase I inhibitor topotecan (SK&F 104864). Cancer Res 1991;51:5813-6.